Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support ...

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support ...

Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation - Arvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE)

Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 million Reaffirms cash runway guidance through the second half of 2028 NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) t…